Galectin Therapeutics (GALT) Lowered to Strong Sell at ValuEngine

Galectin Therapeutics (NASDAQ:GALT) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Sunday, December 31st.

A number of other research firms also recently issued reports on GALT. HC Wainwright upped their price target on shares of Galectin Therapeutics from $3.50 to $6.00 and gave the company a “buy” rating in a research note on Tuesday, November 28th. Roth Capital initiated coverage on shares of Galectin Therapeutics in a research note on Thursday, October 19th. They set a “buy” rating and a $8.00 price target on the stock. Seaport Global Securities reiterated a “buy” rating and set a $5.00 price objective on shares of Galectin Therapeutics in a research report on Friday, October 6th. Finally, Zacks Investment Research cut shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $5.55.

Shares of Galectin Therapeutics (NASDAQ GALT) opened at $5.87 on Friday. The stock has a market cap of $209.20, a price-to-earnings ratio of -10.48 and a beta of 2.54. Galectin Therapeutics has a 12 month low of $0.94 and a 12 month high of $6.15.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Tuesday, November 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. analysts predict that Galectin Therapeutics will post -0.52 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. Advisor Group Inc. increased its position in Galectin Therapeutics by 7.4% during the third quarter. Advisor Group Inc. now owns 519,850 shares of the company’s stock valued at $1,112,000 after acquiring an additional 35,850 shares during the last quarter. Vanguard Group Inc. increased its position in Galectin Therapeutics by 18.2% during the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock valued at $2,144,000 after acquiring an additional 134,165 shares during the last quarter. Virtu KCG Holdings LLC increased its position in Galectin Therapeutics by 24.4% during the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock valued at $264,000 after acquiring an additional 21,008 shares during the last quarter. Finally, Northern Trust Corp increased its position in Galectin Therapeutics by 4.4% during the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after acquiring an additional 3,176 shares during the last quarter. Institutional investors and hedge funds own 10.77% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://ledgergazette.com/2018/01/16/galectin-therapeutics-galt-lowered-to-strong-sell-at-valuengine.html.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply